Mangoceuticals (MGRX) Other Accumulated Expenses (2024 - 2026)

Mangoceuticals (MGRX) has 3 years of Other Accumulated Expenses data on file, last reported at $20056.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 92.02% year-over-year to $20056.0; the trailing twelve-month figure through Mar 2026 stood at $20056.0 (down 92.02% YoY), and the FY2025 full-year result was $156642.0, down 58.0% from the prior year.
• Other Accumulated Expenses retreated to $20056.0 in Q1 2026, from $156642.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $400000.0 in Q2 2024 to a low of $9175.0 in Q2 2025.
• A 3-year average of $218247.6 and a median of $206054.0 in 2025 frame the typical range for Other Accumulated Expenses.
• Peak annual rise in Other Accumulated Expenses reached 57.15% in 2025, while the deepest fall reached 97.71% in 2025.
• Tracing MGRX's Other Accumulated Expenses over 3 years: stood at $373000.0 in 2024, then tumbled by 58.0% to $156642.0 in 2025, then tumbled by 87.2% to $20056.0 in 2026.
• Business Quant data shows MGRX's Other Accumulated Expenses at $20056.0 in Q1 2026, $156642.0 in Q4 2025, and $160684.0 in Q3 2025.